Vanguard Group Inc. increased its position in shares of Exactech, Inc. (NASDAQ:EXAC) by 3.4% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 408,659 shares of the medical equipment provider’s stock after buying an additional 13,263 shares during the period. Vanguard Group Inc. owned about 2.86% of Exactech worth $10,299,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently made changes to their positions in EXAC. Wells Fargo & Company MN increased its stake in shares of Exactech by 13.0% in the first quarter. Wells Fargo & Company MN now owns 57,447 shares of the medical equipment provider’s stock worth $1,448,000 after buying an additional 6,590 shares in the last quarter. Wedge Capital Management L L P NC increased its stake in shares of Exactech by 22.1% in the first quarter. Wedge Capital Management L L P NC now owns 51,300 shares of the medical equipment provider’s stock worth $1,293,000 after buying an additional 9,300 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Exactech by 7.0% in the first quarter. Bank of New York Mellon Corp now owns 61,951 shares of the medical equipment provider’s stock worth $1,562,000 after buying an additional 4,078 shares in the last quarter. TFS Capital LLC bought a new stake in shares of Exactech during the first quarter worth about $1,157,000. Finally, Nine Chapters Capital Management LLC bought a new stake in shares of Exactech during the first quarter worth about $312,000. Institutional investors own 64.58% of the company’s stock.

Shares of Exactech, Inc. (NASDAQ:EXAC) traded up 2.29% during mid-day trading on Friday, reaching $31.25. 32,258 shares of the company’s stock were exchanged. The company’s 50 day moving average is $29.74 and its 200 day moving average is $28.51. Exactech, Inc. has a 1-year low of $22.20 and a 1-year high of $31.90. The stock has a market capitalization of $448.38 million, a PE ratio of 600.96 and a beta of 1.02.

Exactech (NASDAQ:EXAC) last posted its quarterly earnings data on Thursday, July 27th. The medical equipment provider reported $0.33 earnings per share for the quarter, hitting the Zacks’ consensus estimate of $0.33. The company had revenue of $67.30 million during the quarter, compared to analysts’ expectations of $67.75 million. Exactech had a net margin of 0.30% and a return on equity of 7.39%. The firm’s revenue for the quarter was up 1.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.31 earnings per share. Equities research analysts anticipate that Exactech, Inc. will post $1.29 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by TheOlympiaReport and is owned by of TheOlympiaReport. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://theolympiareport.com/2017/09/02/vanguard-group-inc-raises-position-in-exactech-inc-exac.html.

EXAC has been the topic of a number of research reports. BidaskClub downgraded shares of Exactech from a “hold” rating to a “sell” rating in a report on Monday, July 31st. Gabelli reiterated a “buy” rating on shares of Exactech in a report on Monday, July 31st.

In other Exactech news, Director Fern Watts sold 1,013 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total transaction of $29,417.52. Following the completion of the transaction, the director now directly owns 4,727 shares in the company, valued at $137,272.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 28.30% of the company’s stock.

About Exactech

Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.

Want to see what other hedge funds are holding EXAC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exactech, Inc. (NASDAQ:EXAC).

Institutional Ownership by Quarter for Exactech (NASDAQ:EXAC)

Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.